Ratiopharm plots 600 layoffs

Ratiopharm plans to cut 600 jobs over the next 18 months, as it seeks to reduce its annual operating costs by approximately €100 million. The move will affect one in nine of the company's global workforce of 5,400 staff. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.